NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: AstraZeneca
Conditions: Hemorrhage
Interventions: Andexanet alfa
Countries: Netherlands
This is an observational retrospective database study of hospitalized patients treated with andexanet alfa in approximately 10 Dutch hospitals. Currently there is limited information on the patient characteristics and outcomes of patients who are treated with andexanet alfa in The Netherlands and how it is used. This is of interest for treating clinicians because there is a need for a patient profile, also due to the on par position of andexanet alfa with PCC in the Dutch national guideline. Analysis of the data showed that 14 patients of the 218 patients included in the study (6.4%) experienced a thrombotic event (TE) within 30 days after treatment with andexanet alfa. The protocol was amended to allow for an in depth analysis of the 14 TE cases.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Age ≥ 18 years * Received at least one dose of andexanet alfa Exclusion Criteria: None
- Amsterdam, Netherlands